Skip to main content
SpringerLink
Log in

Oncosurgical Strategies for Unresectable Liver Metastases

  • Chapter
  • First Online:
Liver Metastases

  • 907 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspectives. Ann Surg. 1989; 210: 127–38.

    Article  PubMed  Google Scholar 

  2. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006; 94: 982–99.

    Article  PubMed  CAS  Google Scholar 

  3. Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases. Ann Surg. 2006; 244: 524–35.

    Article  PubMed  Google Scholar 

  4. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309–18.

    Article  PubMed  CAS  Google Scholar 

  5. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996; 77: 1254–62.

    Article  PubMed  CAS  Google Scholar 

  6. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005; 241: 715–22.

    Article  PubMed  Google Scholar 

  7. Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000; 127: 512–9.

    Article  PubMed  CAS  Google Scholar 

  8. Levi F, Zidani R, Brienza S, et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer. 1999; 85: 2532–40.

    Article  PubMed  CAS  Google Scholar 

  9. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229–37.

    Article  PubMed  CAS  Google Scholar 

  10. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992; 69: 893–900

    Article  PubMed  CAS  Google Scholar 

  11. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet. 1997; 350: 681–6.

    Article  PubMed  CAS  Google Scholar 

  12. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996; 224: 509–22.

    Article  PubMed  CAS  Google Scholar 

  13. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004; 240: 644–57.

    Article  PubMed  Google Scholar 

  14. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006; 13: 58–65.

    Article  PubMed  Google Scholar 

  15. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999; 10: 663–9.

    Article  PubMed  CAS  Google Scholar 

  16. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004; 15: 933–9.

    Article  PubMed  CAS  Google Scholar 

  17. de la Camera J, Rodriguez J, Rotellar F. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol. 2004; 23: Abstract 3593.

    Google Scholar 

  18. Quenet F, Nordlinger B, Rivoire M. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): a prospective phase II trial. Proc Am Soc Clin Oncol. 2004; 23: Abstract 3613.

    Google Scholar 

  19. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005; 23: 9243–9.

    Article  PubMed  CAS  Google Scholar 

  20. Ho WM, Ma B, Mok T, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol. 2005; 22: 303–12.

    Article  PubMed  CAS  Google Scholar 

  21. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004; 240: 1052–61.

    Article  PubMed  Google Scholar 

  22. Baselga J. The EGFR as a target for anticancer therapy—focus on cetuximab. Eur J Cancer. 2001; 37 Suppl 4: S16–22.

    Article  PubMed  CAS  Google Scholar 

  23. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol. 2006; 17: 450–6.

    Article  PubMed  CAS  Google Scholar 

  24. Kopetz S, Abbruzzese JL, Eng C, et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I; 24: Abstract 3579.

    Google Scholar 

  25. Peeters M, Raoul J, van Laethem J, et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). Eur J Cancer. 2005; 3(suppl): 188.

    Google Scholar 

  26. Cervantes A, Casado E, van Cutsem E, et al. Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)folinic acid (FA) (FOLFOX4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study. Eur J Cancer. 2005; 3(suppl): 181–2.

    Google Scholar 

  27. Adam R, Aloia T, Levi F, et al. Hepatic resection following rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007; 25(29): 4593–602.

    Article  PubMed  CAS  Google Scholar 

  28. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007; 7: 91.

    Article  PubMed  Google Scholar 

  29. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006; 24: 3939–45.

    Article  PubMed  Google Scholar 

  30. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006; 243: 1–7.

    Article  PubMed  Google Scholar 

  31. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004; 15: 460–6.

    Article  PubMed  CAS  Google Scholar 

  32. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 24: 2065–72.

    Article  PubMed  CAS  Google Scholar 

  33. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006; 24: 4983–90.

    Article  PubMed  CAS  Google Scholar 

  34. Takayasu K, Muramatsu Y, Shima Y, et al. Hepatic lobar atrophy following obstruction of the ipsilateral portal vein from hilar cholangiocarcinoma. Radiology. 1986; 160: 389–93.

    PubMed  CAS  Google Scholar 

  35. Kinoshita H, Sakai K, Hirohashi K, et al. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986; 10: 803–8.

    Article  PubMed  CAS  Google Scholar 

  36. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990; 107: 521–7.

    PubMed  CAS  Google Scholar 

  37. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000; 231: 480–6.

    Article  PubMed  CAS  Google Scholar 

  38. Selzner N, Pestalozzi B.C., Kadry Z, et al. Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy. Br J Surg. 2006; 93: 587–92.

    Google Scholar 

  39. Elias D, Baton O, Sideris L, et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol. 2005; 90: 36–42.

    Article  PubMed  Google Scholar 

  40. Rivoire M, De Cian F, Meeus P, et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002; 95: 2283–92.

    Article  PubMed  CAS  Google Scholar 

  41. Adam R, Laurent A, Azoulay D, et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg. 2000; 232: 777–85.

    Article  PubMed  CAS  Google Scholar 

  42. Jaeck D, Oussoultzoglou E, Rosso E, et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004; 240: 1037–49.

    Article  PubMed  Google Scholar 

  43. Togo, S, Nagano Y, Masui H, et al. Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer. Hepatogastroenterology. 2005; 52: 913–9.

    PubMed  Google Scholar 

  44. Heaney JP, Stanton WK, Halbert DS, et al. An improved technic for vascular isolation of the liver: experimental study and case reports. Ann Surg. 1966; 163: 237–41.

    Article  PubMed  CAS  Google Scholar 

  45. Bismuth H, Castaing D, Garden OJ. Major hepatic resection under total vascular exclusion. Ann Surg. 1989; 210: 13–9.

    Article  PubMed  CAS  Google Scholar 

  46. Iwatsuki S, Todo S, Starzl TE. Right trisegmentectomy with a synthetic vena cava graft. Arch Surg. 1988; 123: 1021–2.

    Article  PubMed  CAS  Google Scholar 

  47. Cherqui D, Malassagne B, Colau PI, et al. Hepatic vascular exclusion with preservation of the caval flow for liver resections. Ann Surg. 1999; 230: 24–30.

    Article  PubMed  CAS  Google Scholar 

  48. Huguet C, Gavelli A, Chieco PA, et al. Liver ischemia for hepatic resection: where is the limit? Surgery. 1992; 111: 251–9.

    PubMed  CAS  Google Scholar 

  49. Azoulay D, Eshkenazy R, Andreani P, et al. In situ hypothermic perfusion of the liver versus standard total vascular exclusion for complex liver resection. Ann Surg. 2005; 241: 277–85.

    Article  PubMed  Google Scholar 

  50. Azoulay D, Andreani P, Maggi U, et al. Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience. Ann Surg. 2006; 244: 80–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Professor, Centre Hépato-Biliaire, AP-HP, Hôpital Paul Brousse, Villejuif, France

    René Adam

Authors
  1. Robbert J. de Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dennis A. Wicherts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. René Adam
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, Dept. Surgical Oncology, University of Texas, Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Jean-Nicolas Vauthey

  2. São Paulo, Faculdade de Medicina da, Universidade de São Paulo,, Instituto do Cancer do Estado de, Ave Dr Arnaldo 251, São Paulo, 01246-000, São Paulo, Brazil

    Paulo M. Hoff

  3. University of Liverpool, St Helens Teach, Marshalls Cross Road, St Helens, WA9 3DA, United Kingdom

    Riccardo A. Audisio

  4. Center for Digestive Diseases, University Hospital Aintree, Lower Lane, Liverpool, L9 7AL, United Kingdom

    Graeme J. Poston

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London

About this chapter

Cite this chapter

de Haas, R.J., Wicherts, D.A., Adam, R. (2009). Oncosurgical Strategies for Unresectable Liver Metastases. In: Vauthey, JN., Hoff, P., Audisio, R., Poston, G. (eds) Liver Metastases. Springer, London. https://doi.org/10.1007/978-1-84628-947-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-947-7_7

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-946-0

  • Online ISBN: 978-1-84628-947-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation